SUPERNUS PHARMACEUTICALS, INC. - 8-K Filing

Supernus Pharmaceuticals receives seven years of FDA orphan-drug exclusivity for ONAPGO and submits sNDA for second supplier. (Items: 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $SUPN

Read the full article at SEC EDGAR

More Regulatory news